{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:52:19Z","timestamp":1753883539967,"version":"3.41.2"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Optimal survival outcomes of prostate cancer are best achieved through high-quality care for curable disease. In Nigeria, various barriers may impede the curative treatment of prostate cancer, yet their impact on care and patient outcomes remains anecdotal. This study assessed treatment quality, survival outcomes, and interhospital differences of these metrics among patients with clinically localized prostate cancer in Nigeria.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>A retrospective study of patients with clinical stage T1-T3a, M0 prostate cancer at three tertiary hospitals in Nigeria over a 3-year period was conducted. Data on hospital sites, sociodemographics, clinicopathologic characteristics, quality metrics, imaging used, treatment, and survival status were collected. The primary end point was time from diagnosis to first treatment. Secondary end points were time from presentation to diagnosis, other prostate cancer quality metrics, all-cause survival, and interhospital differences in these metrics. Quality of diagnostics, treatments, and other outcomes were described and compared using Cox regression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>This study included 110 patients with a median age of 67 years. Most (n = 66, 61%) had high-risk disease. The median time from tertiary hospital presentation to diagnosis was 31 days. Median time from diagnosis to first treatment of any type was 68 days, with radical radiotherapy was 117 days, and with radical prostatectomy was 104 days. Eighteen percent (n = 20) had guideline-concordant imaging for tumor staging, 67 patients (61%) received any treatment or active surveillance, and retention in care was 42%. Three-year all-cause survival was 41%. There was a significant difference in most quality metrics including guideline-concordant imaging and treatment across the hospital sites.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Time to treatment was delayed beyond international benchmarks; quality of staging, treatment, and care process were suboptimal; and survival was poor amid geographical disparities in care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/go-24-00504","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T20:00:04Z","timestamp":1742846404000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Quality of Care and Survival Outcomes Among Patients With Clinically Localized Prostate Cancer in Nigeria"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4296-9744","authenticated-orcid":true,"given":"Musliu Adetola","family":"Tolani","sequence":"first","affiliation":[{"name":"Ahmadu Bello University Teaching Hospital, Ahmadu Bello University, Zaria, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5889-309X","authenticated-orcid":true,"given":"Christian Agbo","family":"Agbo","sequence":"additional","affiliation":[{"name":"Benue State University Teaching Hospital, Makurdi, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3900-882X","authenticated-orcid":true,"given":"Alan","family":"Paciorek","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehu Salihu","family":"Umar","sequence":"additional","affiliation":[{"name":"Ahmadu Bello University Teaching Hospital, Ahmadu Bello University, Zaria, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rufus Wale","family":"Ojewola","sequence":"additional","affiliation":[{"name":"Lagos University Teaching Hospital, University of Lagos, Idi-Araba, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2319-8948","authenticated-orcid":true,"given":"Faruk","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Ahmadu Bello University Teaching Hospital, Ahmadu Bello University, Zaria, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4250-9756","authenticated-orcid":true,"given":"Ernie","family":"Kaninjing","sequence":"additional","affiliation":[{"name":"Georgia College and State University, Milledgeville, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4657-6702","authenticated-orcid":true,"given":"Muhammed","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Ahmadu Bello University Teaching Hospital, Ahmadu Bello University, Zaria, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8083-1290","authenticated-orcid":true,"given":"Rebecca","family":"DeBoer","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"doi-asserted-by":"publisher","key":"e_1_3_8_2_2","DOI":"10.3322\/caac.21660"},{"doi-asserted-by":"publisher","key":"e_1_3_8_3_2","DOI":"10.1002\/pros.23923"},{"doi-asserted-by":"publisher","key":"e_1_3_8_4_2","DOI":"10.3390\/genes11121471"},{"doi-asserted-by":"publisher","key":"e_1_3_8_5_2","DOI":"10.1016\/S1470-2045(19)30456-5"},{"doi-asserted-by":"publisher","key":"e_1_3_8_6_2","DOI":"10.1002\/cncr.33818"},{"key":"e_1_3_8_7_2","first-page":"411","article-title":"Barriers and facilitators of the application of precision medicine to the genitourinary cancer care pathway: Perspective from a low- and middle- income country in sub-Saharan Africa","volume":"42","author":"Tolani MA","year":"2024","unstructured":"Tolani MA, Zubairu IH, Balarabe K, et al: Barriers and facilitators of the application of precision medicine to the genitourinary cancer care pathway: Perspective from a low- and middle- income country in sub-Saharan Africa. Urol Oncol Semin Orig Investig 42:411-420, 2024","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"e_1_3_8_8_2","article-title":"Status of government-funded radiotherapy services in Nigeria","author":"Aruah SC","unstructured":"Aruah SC, Chidebe RCW, Orjiakor TC, et al: Status of government-funded radiotherapy services in Nigeria. JCO Glob Oncol 10.1200\/GO.22.00406","journal-title":"JCO Glob Oncol"},{"doi-asserted-by":"publisher","key":"e_1_3_8_9_2","DOI":"10.1002\/cncr.33815"},{"key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/07357907.2021.1933009","article-title":"Factors influencing help-seeking behavior in men with symptoms of prostate cancer: A qualitative study using an ecological perspective","volume":"39","author":"Ezenwankwo EF","year":"2021","unstructured":"Ezenwankwo EF, Oladoyimbo CA, Dogo HM, et al: Factors influencing help-seeking behavior in men with symptoms of prostate cancer: A qualitative study using an ecological perspective. Cancer Invest 39:529-538, 2021","journal-title":"Cancer Invest"},{"doi-asserted-by":"publisher","key":"e_1_3_8_11_2","DOI":"10.1634\/theoncologist.2019-0804"},{"unstructured":"Quality oncology practice initiative 2021 reporting tracks. American Society of Clinical Oncology. https:\/\/practice.asco.org\/sites\/default\/files\/drupalfiles\/QOPI_2021_Round_2_Reporting_Track__Public_Posting.pdf","key":"e_1_3_8_12_2"},{"unstructured":"Litwin MS Steinberg M Malin J et al: Prostate cancer patient outcomes and choice of providers: Development of an infrastructure for quality assessment. Research and Development (RAND) Corporation. http:\/\/www.rand.org\/content\/dam\/rand\/pubs\/monograph_reports\/2005\/MR1227.pdf","key":"e_1_3_8_13_2"},{"key":"e_1_3_8_14_2","first-page":"217","article-title":"Utilization of prostate cancer quality metrics for research and quality improvement: A structured review","volume":"45","author":"Gori D","year":"2019","unstructured":"Gori D, Dulal R, Blayney DW, et al: Utilization of prostate cancer quality metrics for research and quality improvement: A structured review. Jt Comm J Qual Patient Saf 45:217-226, 2019","journal-title":"Jt Comm J Qual Patient Saf"},{"unstructured":"Mottet N Cornford P van den Bergh RCN et al: EAU-EANM-ESTRO-ESUR-SIOG: Guidelines on prostate cancer. EAU 2020 pp 1-182","key":"e_1_3_8_15_2"},{"doi-asserted-by":"publisher","key":"e_1_3_8_16_2","DOI":"10.1016\/j.puhe.2023.07.015"},{"doi-asserted-by":"publisher","key":"e_1_3_8_17_2","DOI":"10.1200\/OP.23.00040"},{"doi-asserted-by":"publisher","key":"e_1_3_8_18_2","DOI":"10.1634\/theoncologist.2018-0535"},{"key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/5534683","article-title":"Waiting times for prostate cancer diagnosis in a Nigerian population","volume":"2021","author":"Omisanjo OA","year":"2021","unstructured":"Omisanjo OA, Ogunremi OO, Akinola OO, et al: Waiting times for prostate cancer diagnosis in a Nigerian population. J Cancer Epidemiol 2021:1-6, 2021","journal-title":"J Cancer Epidemiol"},{"doi-asserted-by":"publisher","key":"e_1_3_8_20_2","DOI":"10.3390\/ijerph16030342"},{"key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7196\/SAMJ.9192","article-title":"Waiting times for prostate cancer diagnosis in Kwazulu-Natal, South Africa","volume":"105","author":"Singh K","year":"2015","unstructured":"Singh K, Abdel Goad EH, Ramklass SS: Waiting times for prostate cancer diagnosis in Kwazulu-Natal, South Africa. S Afr Med J 105:484-486, 2015","journal-title":"S Afr Med J"},{"key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1186\/s12913-024-11340-1","article-title":"Detection and management of localized prostate cancer in Nigeria: Barriers and facilitators according to patients, caregivers and healthcare providers","volume":"24","author":"Tolani MA","year":"2024","unstructured":"Tolani MA, Agbo CA, Paciorek A, et al: Detection and management of localized prostate cancer in Nigeria: Barriers and facilitators according to patients, caregivers and healthcare providers. BMC Health Serv Res 24:918, 2024","journal-title":"BMC Health Serv Res"},{"key":"e_1_3_8_23_2","article-title":"Breast cancer care quality in South Africa\u2019s public health system: An evaluation using American Society of Clinical Oncology\/National Quality Forum measures","author":"O\u2019Neil DS","unstructured":"O\u2019Neil DS, Chen WC, Ayeni O, et al: Breast cancer care quality in South Africa\u2019s public health system: An evaluation using American Society of Clinical Oncology\/National Quality Forum measures. JCO Glob Oncol 10.1200\/JGO.19.00171","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"1811722","DOI":"10.1001\/jamanetworkopen.2018.1172","article-title":"Association between guideline-discordant prostate cancer imaging rates and health care service among veterans and Medicare recipients","volume":"1","author":"Makarov DV","year":"2018","unstructured":"Makarov DV, Ciprut S, Walter D, et al: Association between guideline-discordant prostate cancer imaging rates and health care service among veterans and Medicare recipients. JAMA Netw Open 1:1811722, 2018","journal-title":"JAMA Netw Open"},{"key":"e_1_3_8_25_2","first-page":"1138","article-title":"Usefulness of prostate specific antigen density in prostate cancer detection among men with PSA of 4-10 ng\/ml","volume":"10","author":"Agbo C","year":"2020","unstructured":"Agbo C, Ramyil V, Dakum N, et al: Usefulness of prostate specific antigen density in prostate cancer detection among men with PSA of 4-10 ng\/ml. Ann Med Health Sci Res 10:1138-1141, 2020","journal-title":"Ann Med Health Sci Res"},{"key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.11604\/pamj.2013.15.129.2489","article-title":"Prevalence and characteristics of prostate cancer among participants of a community based screening in Nigeria using serum prostate specific antigen and digital rectal examination","volume":"15","author":"Ikuerowo SO","year":"2013","unstructured":"Ikuerowo SO, Omisanjo OA, Bioku MJ, et al: Prevalence and characteristics of prostate cancer among participants of a community based screening in Nigeria using serum prostate specific antigen and digital rectal examination. Pan Afr Med J 15:129, 2013","journal-title":"Pan Afr Med J"},{"doi-asserted-by":"publisher","key":"e_1_3_8_27_2","DOI":"10.1007\/s10552-021-01453-x"},{"key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1097\/JU.0000000000001531","article-title":"Other and all-cause mortality among men diagnosed with prostate cancer in the PLCO trial","volume":"205","author":"Pierre-Victor D","year":"2021","unstructured":"Pierre-Victor D, Pinsky PF, Miller E, et al: Other and all-cause mortality among men diagnosed with prostate cancer in the PLCO trial. J Urol 205:1372-1378, 2021","journal-title":"J Urol"},{"doi-asserted-by":"publisher","key":"e_1_3_8_29_2","DOI":"10.1111\/bju.14659"},{"doi-asserted-by":"publisher","key":"e_1_3_8_30_2","DOI":"10.3389\/fonc.2021.650117"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-24-00504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T20:01:57Z","timestamp":1742846517000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-24-00504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1200\/GO-24-00504"],"URL":"https:\/\/doi.org\/10.1200\/go-24-00504","relation":{},"ISSN":["2687-8941"],"issn-type":[{"type":"electronic","value":"2687-8941"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400504"}}